Uganda Tuberculosis Implementation Research Consortium
Kampala, Uganda
NCT Number: NCT05640648
In a previous randomized control trial, the investigators identified gaps in the implementation of tuberculosis (TB) contact investigation at multiple levels of the service delivery cascade. Drawing on prior experiences, the investigators have recently developed a novel strategy to enhance the implementation of routine contact investigation procedures. This user-centered implementation strategy was created through serial prototyping guided by human-centered design (HCD) and employs communities of practice (CoP) as an adjunctive adaptation and sustainment strategy. The investigators are now conducting a stepped-wedge, cluster-randomized implementation trial in 12 study sites in Uganda to determine if the resulting user-centered implementation strategy enhances the delivery of TB contact investigation and other implementation outcomes, and also improves health outcomes.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Kampala, Uganda
The trial has 3 major aims: (1) to compare the implementation, effectiveness, and public health impact of TB contact investigation delivered via an enhanced, "user-centered" implementation strategy versus a standard implementation strategy in a stepped-wedge, cluster-randomized implementation trial; (2) to identify processes and contextual factors that influence the implementation, effectiveness, and public health impact of the enhanced delivery strategy for TB contact investigation; and (3) to compare the costs and epidemiological impact of the enhanced and standard implementation strategies for TB contact investigation. The enhanced, user-centered strategy will employ two major components: a) a branded, participant-centered strategy consisting of implementation facilitation tools previously developed using human-centered design; and b) Communities of Practice, a community-health worker-centered, continuous quality improvement strategy. The goal is to improve the delivery of standard TB contact investigation following Uganda National TB & Leprosy Programme guidelines. The investigators hypothesize that the enhanced, user-centered strategy will result in a greater proportion of close contacts completing TB evaluation than the standard strategy. They further hypothesize that successful implementation will be deemed feasible, acceptable, and appropriate by patients and CHWs and that it will increase self-efficacy and perceived social support among CHWs. Finally, the investigators hypothesize that models evaluating the impact of the user-centered strategy when delivered nationwide will find it cost-effective and able to reduce national TB incidence over a 10-year horizon.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Health centre inclusion criteria:
Health centre exclusion criteria:
Individual inclusion criteria for index persons with TB (also known as index TB patients or TB cases):
Individual exclusion criteria for index persons with TB :
Inclusion criteria
for close contacts:
Exclusion criteria
for close contacts:
Other names: Enhanced Contact Investigation Implementation Strategy
Once an eligible TB patient agrees to participate, CHWs will visit the patient to assess the eligibility of close contacts to participate. For eligible contacts who agree to participate, the CHW will perform TB symptom screening and arrange subsequent microbiologic, clinical, and/or radiographic evaluation. Those screening TB symptom-positive will be asked to expectorate a sputum sample, unless under age 5. If under age 5 or unable to produce sputum, contacts will be referred to the health centre for evaluation. A CHW will transport sputum samples to the health-centre laboratory for microbiologic evaluation and later report the test results back to the contact. During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
Other names: Usual Implementation Strategy
Time frame: 60 days
The percentage of participants (close contacts) who are experiencing TB symptoms who complete TB evaluation within 60 days of the TB patient's treatment initiation date
Time frame: 60 days
The difference between study periods in percentage of contacts diagnosed with active TB and initiated on treatment within 60 days of the TB patient's treatment initiation
Time frame: 60 days
The difference between study periods in percentage of contacts initiating TB preventative therapy (TPT) within 60 days of the TB patient's treatment initiation
Time frame: 60 days
The difference between study periods in counts of the number of contacts diagnosed with active TB
Time frame: 60 days
The difference between study periods in counts of the number of contacts initiating TPT
Time frame: 60 days
The difference between study periods in percentage of all TB cases among contacts
Yale University
Other
Human-centered Design and Communities of Practice to Improve Delivery of Home-based Tuberculosis Contact Investigation in Uganda
Acronym: HCD-CoP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05007821
Actinomycetales Infections, Bacterial Infections
Gaborone, South-East District, Botswana
View Trial DetailsNCT04865536
Actinomycetales Infections, Bacterial Infections
Fair Lawn, New Jersey, United States
View Trial DetailsNCT04493671
Actinomycetales Infections, Bacterial Infections
San Antonio, Texas, United States
View Trial DetailsNCT02715271
Actinomycetales Infections, Bacterial Infections
Tbilisi, Georgia
View Trial Details